India to spend $79.6 million to strengthen drug regulatory system

<html xmlns=""><head><title>India to spend $79.6 million to strengthen drug regulatory system</title></head><body>

NEW DELHI, Feb 3 (Reuters) -India will spend $79.6 million on strengthening its drug regulatory system, the health minister said on Friday, after the World Health Organization raised concerns about domestically produced cough syrups being linked to the death of 89 children in two countries.

India is known as the "pharmacy of the world" and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22. The death of at least 70 children in Gambia and 19 children in Uzbekistan last year have dented that image.

Government data shared by Health Minister Mansukh Mandaviya on Friday showed that out of nearly 89,000 drug samples tested in 2021-22 by states and territories, more than 2,500 did not meet standards and close to 380 were declared spurious or adulterated.

Mandaviya said the federal government has allocated funds to his ministry for measures including setting up new drug testing laboratories and upgrading existing ones.

"The government has taken various regulatory measures to ensure the quality of medicines in the country," he said in a written reply to a question in parliament.

It was not immediately clear when the funds would be provided nor how they would be used. The health ministry did not immediately respond to a Reuters request seeking clarity.

Last month the WHO called for "immediate and concerted action" to protect children from contaminated medicines.

The WHO, the U.S. Food and Drug Administration and foreign regulatory authorities have launched an investigation into the source of contaminated cough syrups that have killed more than 300 children in Africa and Asia.

The companies whose syrups were linked to the death of children have either denied that their products were contaminated or declined to comment while investigations are ongoing.

In the case of Gambia, Indian government inspectors found no contamination in test samples of the syrup linked to the death of children.

($1 = 81.8690 Indian rupees)

Reporting by Shivam Patel in New Delhi; Editing by Kirsten Donovan


Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.